NCT04137822No Longer Available不适用
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Impatients N.V. trading as myTomorrows2 个研究点 分布在 2 个国家开始时间: 2019年10月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 2
研究概览
简要总结
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
详细描述
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms.
Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
排除标准
- •Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).
研究者
研究点 (2)
Loading locations...
相似试验
No Longer Available
不适用
An Expanded Access Program for AM0010 (Pegilodecakin)Colorectal CarcinomaPancreatic CarcinomaNon-small Cell Lung CarcinomaSolid TumorsBreast CancerProstate CancerOvarian CancerMelanomaRenal Cell CarcinomaNCT03554434Eli Lilly and Company
已完成
2 期
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT01303172Immodulon Therapeutics Ltd110
No Longer Available
不适用
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and GliomasGlioma of BrainGlioblastomaNCT03460782Center Trials & Treatment
Approved For Marketing
不适用
Expanded Access for IMMU-132Metastatic Triple-Negative Breast CarcinomaNCT04320693Gilead Sciences
No Longer Available
不适用
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage TherapeuticNCT03395743Armata Pharmaceuticals, Inc.